Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Author Archives: "Coach" Israel Barken M.D.
Cryo Immunotherapy Part 2
Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel Barken from the Prostate Research and Education Foundation. Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed. Suggestions … Continue reading
Cryoablation Immuno Therapy
Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease. Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- … Continue reading
Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy
Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author: Anthony V. D’Amico Source: Clinical Genitourinary Cancer. March 5, 2015
Active Surveillance In Intermediate-Risk Prostate Cancer
Active Surveillance In Intermediate-Risk Prostate Cancer Called Into Question. https://youtu.be/dBk3z2T9KwQ Dr. Israel Barken brings info about higher risk of cancer specific mortality in the intermediate prostate cancer risk group. The study presentor at the GenitoUrinary Symposium 2015 was Dr. Andrew … Continue reading
Testosterone and the risk of cancer.
Testosterone and the risk of cancer. Dr. Israel Barken , the medical director of the prostate cancer research and education foundation PCREF discusses a recent article in the BJU Int. 2015 Feb;115(2):317-21.. Testosterone therapy and cancer risk. Eisenberg ML1, Li … Continue reading
Circulating Epithelial Tumor Cells and Tumor Spheres
Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres. Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology. She is an expert on Circulating Epithelial Tumor Cells. The … Continue reading
Prostvac Vaccination for Localized Prostate Cancer Disease
Prostvac in Preventing Disease Progression in Patients with Localized Cancer Undergoing Active Surveillance. What is unique about this vaccine study , is the fact that it is given to patients with localized disease. Practically, the patient gets a series of vaccination … Continue reading
What is Liquid Biopsy- The Role of Exosomes
Liquid Biopsy – The Role of Exosomes. Dr. Israel Barken introduces the videos published by Life Technologies from ThermoFisher Technologies. The introduction relates to the importance of using imaging and markers to define recurrent disease and monitor the progression. The … Continue reading
Posted in Biomarker, CETC, CTC, Exosome, Genome, Imaging, Liquid Biopsy, Markers, Treatments for Prostate Cancer
Tagged Recurrent Prostate Cancer
Leave a comment